Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Acute biliary pancreatitis management during the COVID-19 pandemic

View ORCID ProfileElif Colak, Ahmet Burak Ciftci
doi: https://doi.org/10.1101/2021.05.08.21256726
Elif Colak
1University of Samsun, Samsun Training and Research Hospital, Department of General Surgery, Samsun, Turkey
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Elif Colak
  • For correspondence: elifmangancolak{at}hotmail.com
Ahmet Burak Ciftci
1University of Samsun, Samsun Training and Research Hospital, Department of General Surgery, Samsun, Turkey
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Objective To analyze acute biliary pancreatitis (ABP) management during the COVID-19 pandemic.

Methods This was a retrospective cohort study conducted with ABP patients during two discrete periods: a control period from March 16, 2019, through March 15, 2020 (period 1); and a COVID-19 era between March 16, 2020, and March 15, 2021 (period 2).

Results A total of 89 patients with ABP were identified, 58 in period 1 and 31 in period 2, which equates to a 46.6% reduction. The mean age of the patients was 62.75±16.59 years, and 51 (57.3%) of the patients were female. qSOFA and WSES scores are significantly higher in the patients in period 2 (p=0.031, p=0.032). There were no significant differences regarding hematological parameters except lactate. Lactate levels were significantly higher in period 2 (p=0.012). Twenty-two patients (37.9%) in period 1 and six (19.3%) patients in period 2 underwent cholecystectomy (p=0.072). Cholecystectomy was performed laparoscopically in 18 (81.8%) patients in period 1 and in five (83.3%) patients in period 2 (p=0.932). There were no significant differences regarding surgical intervention between the two periods. Three patients were diagnosed COVID-19 in period 2. All of these patients died. The severity of ABP was significantly worse in SARS-CoV-2-positive patients, with over 100% of patients in this group developing severe pancreatitis. Six patients (10.3%) in period 1, 10 (32.2%) patients in period 2 were admitted in ICU (p=0.010). The median length of stay was 5 (1-40) days in period 1 and 4 (2-75) days in period 2 (p= 0.641). The hospital mortality rate was 3.4% and 19.3% in period l and period 2, respectively. Mortality was significantly higher in period 2 (p=0.012).

Conclusion During the COVID-19 outbreak, a significant decrease in the number of patients with ABP and increased severity was observed. Additionally, it can be said that SARS-CoV-2 infection has a mortal course in patients with ABP. Analysis and evaluation of ABP patients during the pandemic period is important to draw conclusions that will help confront future health crises.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This research was not supported by a particular or public statement.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This study was approved by the Review Board of the University of Samsun, Samsun Training and Research Hospital (GOKA/2021/9/8).

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Data available from author on request.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted May 14, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Acute biliary pancreatitis management during the COVID-19 pandemic
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Acute biliary pancreatitis management during the COVID-19 pandemic
Elif Colak, Ahmet Burak Ciftci
medRxiv 2021.05.08.21256726; doi: https://doi.org/10.1101/2021.05.08.21256726
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Acute biliary pancreatitis management during the COVID-19 pandemic
Elif Colak, Ahmet Burak Ciftci
medRxiv 2021.05.08.21256726; doi: https://doi.org/10.1101/2021.05.08.21256726

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Gastroenterology
Subject Areas
All Articles
  • Addiction Medicine (434)
  • Allergy and Immunology (758)
  • Anesthesia (222)
  • Cardiovascular Medicine (3312)
  • Dentistry and Oral Medicine (366)
  • Dermatology (282)
  • Emergency Medicine (479)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1175)
  • Epidemiology (13397)
  • Forensic Medicine (19)
  • Gastroenterology (900)
  • Genetic and Genomic Medicine (5175)
  • Geriatric Medicine (482)
  • Health Economics (785)
  • Health Informatics (3283)
  • Health Policy (1145)
  • Health Systems and Quality Improvement (1198)
  • Hematology (432)
  • HIV/AIDS (1022)
  • Infectious Diseases (except HIV/AIDS) (14650)
  • Intensive Care and Critical Care Medicine (915)
  • Medical Education (478)
  • Medical Ethics (128)
  • Nephrology (525)
  • Neurology (4949)
  • Nursing (262)
  • Nutrition (734)
  • Obstetrics and Gynecology (888)
  • Occupational and Environmental Health (797)
  • Oncology (2530)
  • Ophthalmology (730)
  • Orthopedics (284)
  • Otolaryngology (348)
  • Pain Medicine (323)
  • Palliative Medicine (90)
  • Pathology (547)
  • Pediatrics (1305)
  • Pharmacology and Therapeutics (551)
  • Primary Care Research (558)
  • Psychiatry and Clinical Psychology (4223)
  • Public and Global Health (7525)
  • Radiology and Imaging (1713)
  • Rehabilitation Medicine and Physical Therapy (1018)
  • Respiratory Medicine (981)
  • Rheumatology (480)
  • Sexual and Reproductive Health (500)
  • Sports Medicine (425)
  • Surgery (551)
  • Toxicology (72)
  • Transplantation (237)
  • Urology (206)